经肝动脉化疗栓塞术联合 DC Bead LUMI™显影微球治疗原发性肝癌：初步经验。
Transarterial chemoembolization with DC Bead LUMI™ radiopaque beads for primary liver cancer treatment: preliminary experience.
机构信息
Oncology Radiodiagnostics Department, Oncology Institute of Veneto, Institute for the Research & Treatment of Cancer (IRCC), 35128 Padova, Italy.
Onco-Ematology Department, Azienda Ospedaliera 'Ospedali Riuniti Marche Nord', 61122 Pesaro, Italy.
出版信息
Future Oncol. 2017 Oct;13(25):2243-2252. doi: 10.2217/fon-2017-0364. Epub 2017 Oct 24.
AIM
Primary objectives of the study were to assess the safety of transarterial chemoembolization (TACE) using DC Bead LUMI™ for the treatment of hepatocellular carcinoma and beads distribution after TACE.
PATIENTS/METHODS: This was a prospective observational cohort study. The study included 44 hepatocellular carcinoma patients who were treated with TACE using DC Bead LUMI. Beads distribution was monitored 1 h after TACE by CT scan.
RESULTS
TACE had no intraprocedural complications. Observed side effects were of mild intensity and included pain in 5 (11%), fever in 4 (9%) and vomiting in 2 (5%) patients. Most patients (89%) reported no adverse event. Non-target distribution was observed in only two cases (5%).
CONCLUSION
DC Bead LUMI allowed assessing in real time their distribution. This could prevent non-target infusion and reduce toxicity.
目的
本研究的主要目的是评估使用 DC Bead LUMI™进行经动脉化疗栓塞（TACE）治疗肝细胞癌的安全性和 TACE 后微球的分布情况。
患者/方法：这是一项前瞻性观察性队列研究。研究纳入了 44 例接受 DC Bead LUMI 进行 TACE 治疗的肝细胞癌患者。在 TACE 后 1 小时通过 CT 扫描监测微球的分布情况。
结果
TACE 无术中并发症。观察到的副作用为轻度，包括 5 例（11%）疼痛、4 例（9%）发热和 2 例（5%）呕吐。大多数患者（89%）无不良事件报告。只有 2 例（5%）观察到非靶区分布。
结论
DC Bead LUMI 允许实时评估其分布情况。这可以防止非靶区输注并降低毒性。
Zotero 插件